Empirico at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Empirico at ASHG 2026 in Montréal: 1 presentation (1 poster).

OrganizationASHG 2026 Attendance
1 Scientist
empiri.co|LinkedIn
Private company
Empirico discovers and develops siRNA medicines and genetically validated therapeutic targets with pharmaceutical collaborators.
GSK licensed Empirico's EMP-012 for COPD, paying $85 million upfront plus up to $660 million in milestones, a large pharma validation.
›
GSK licensed Empirico's EMP-012 for COPD, paying $85 million upfront plus up to $660 million in milestones, a large pharma validation.
2025-10 · source
Source: company newsroom
Raised $17M Series A-2 (Jan 2020)
›
Led by Ionis with DCVC Bio and Neotribe Ventures; more recent cash came from the GSK deal. · 2020-01-09
“"closing of its $17 million Series A-2 financing, led by Ionis and with participation by DCVC Bio and Neotribe Ventures."”
Source: funding announcement
Currently hiring: 2 open roles
›
Source: careers page
Poster
Wed Oct 21
2:30 pm
Part of Statistical Genetics and Genetic Epidemiology Poster Wednesday Session
Effect of covariate adjustment on rare and common variant associations in All of Us
Exhibit & Poster Hall · Board 8393W
Complex diseasesGenome-wide association studyLarge-scale biobanksPhenome-wide association

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Empirico

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction